The number of Ki67-positive cells and the microvascular density were both most significantly decreased by the combined use of lenvatinib and cilengitide (Fig. 6E right panel), suggesting a strong inhibitory effect on cancer cell proliferation and angiogenesis in HCC. Here, MKI67 is linked to hepatocellular carcinoma.